Journal of Radiation Protection and Research

The Korean Association for Radiation Protection (대한방사선방어학회)
권호 표지

The Effects of Melatonin and Ge-132 on Acute Hematopoietic Syndrome following Radiation Exposure

방사선피폭 후 급성조혈계증후군에 대한 Melatonin과 Ge-132의 효과

  • 장성순 (가톨릭의대 방사선종양학교실)
  • Published : 2004.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

The radioprotective effects of Melatonin and Ge-132 on acute hematopoietic injury was investigated in mice exposed to an acute whole-body radiation dose of 8 Gy. Melatonin was administered intraperitoneally 1 hour before irradiation at a dose of 200 mg/kg, and Ge-132 was administered orally from days 5 to 20 after irradiation at a dose 130 - 150 mg/kg/d. The radioprotective effects were evaluated for spleen using TUNEL assay, and in peripheral blood by counting lymphocyte & WBC. The 4 experimental groups (irradiation-only, melatonin pretreatment, Ge-132 posttreatment, and melatonin pretreatment plus Ge-132 posttreatment) were observed for survival analysis up to 30 days following irradiation. The apoptotic index (47.8% vs 45.9%, p=0.385), and the number of lymphocytes ($97/{\mu}{\ell}\;vs\;101/{\mu}{\ell}$, p=0.898) were not significantly different between the irradiation-only and the melatonin pretreatment group, But the number of WBCs ($147/{\mu}{\ell}\;vs\;306/{\mu}{\ell}$, p=0.010) was higher in the melatonin pretreatment group. The irradiation-only, melatonin, Ge-132, and melatonin plus Ge-132 treatments resulted in survival rate at 30 days of 21.4%, 100%, 35.7%, and 85.7%, respectively. The melatonin pretreatment group in survival analysis between groups was showed significantly higher survival than the irradiation-only(p=0.000), or Ge-132 posttreatment group(p=0.0003). These results indicate that the melatonin may have a potential as an effective radioprotector on acute hematopoietic syndrome following radiation exposure.

방사선피폭 후 급성조혈계 손상에 대한 Melatonin과 Ge-132의 방어효과를 8 Gy의 선량으로 급성, 전신피폭 된 마우스에서 연구하였다. Melatonin은 피폭 1시간 전에 200 mg/kg의 용량으로 복강 내 주사하였고, Ge-132는 130 - 150 mg/kg/d의 용량으로 피폭 후 5일째부터 20일째까지 경구복용 시켰다. 방사선방어 효과를 평가하기 위해 비장에서 TUNEL assay를 실시하였고 혈액 내 림프구와 총 백혈구 수치를 측정하였다. 피폭 후 30일째까지의 생존분석을 위해 4 실험군들 (피폭단독군, melatonin 전처치군, Ge-132 후처치군, melatonin 전처치 및 Ge-132 후처치군)에서 날짜경과에 따른 사망을 측정하였다. 피폭단독군과 melatonin 전처치군 간에 세포고사지수 (47.8% vs 45.9%, p=0.385)와 림프구 수치 ($97/{\mu}{\ell}\;vs\;101/{\mu}{\ell}$, p=0.898)에서 차이가 없었으나, 총 백혈구 수치는 melatonin 전처치군에서 유의하게 높은 수치 ($147/{\mu}{\ell}\;vs\;306/{\mu}{\ell}$, p=0.010)를 보였다. 피폭 후 30일째의 생존율은 피폭단독군, melatonin 전처치군, Ge-132 후처치군, 그리고 melatonin 전처치 및 Ge-132 후처치군에서 각각 21.4%, 100%, 35.7%, 그리고 85.7%였다. 실험군들 간의 생존분석에서 melatonin 전처치 군은 피폭단독군(p=0.000)이나 Ge-132 후처치군(p=0.0003)에 유의하게 높은 생존을 보였다. 본 연구결과는 방사선피폭 후 급성조혈계증후군에 대하여 melatonin이 방사선방어제로서 효능을 지님을 보여주고 있다.

Keywords

References

  1. E.J. Hall, Radiobiology for the Radiologist, 5th Ed., pp. 124-135, Lippincott,Philadelphia(2000)
  2. D. Antonadou, M. Pepelassi, M. Synodinou, M. Puglisi and N. Throuvalas, 'Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer,' Int J Radiat Oncol Biol Phys, 52(3), 739-747(2002)
  3. D.M. Brizel, T.H. Wasserman, M. Henke, V. Strnad, V. Rudat, A. Monnier, F. Eschwege, J. Zhang, L. Russell, W. Oster and R. Sauer, 'Phase III randomized trial of amifostine as a radioprotector in head and neck cancer,' J Clin Oncol, 18(19), 3339-3345(2000)
  4. D. Antonadou, N. Coliarakis, M. Synodinou, H. Athanassiou, A. Kouveli, C. Verigos, G. Georgakopoulos, K. Panoussaki, P. Karageorgis and N. Throuvalas, 'Randomized phase III trial of radiation treatment +/ - arnifostine in patients with advanced-stage lung cancer,' Int J Radiat Oneal Biol Phys, 51(4), 915-922(2001)
  5. A. Brzezinski, 'Melatonin in humans,' N Engl J Med, 336(3), 186-195(1997)
  6. M. Karbownik and R.J. Reiter, 'Antioxidative effects of melatonin in protection against cellular damage caused by ionizing radiation,' Proc Soc Exp Biol Med, 225(1), 9-22(2000) https://doi.org/10.1046/j.1525-1373.2000.22502.x
  7. P. Lissoni, S. Pittalis, F. Brivio, E. Tisi, F. Rovelli, A. Ardizzoia, S. Barni, G. Tancini, G. Giudici and A. Biondi, 'In vitro modulatory effects of interleukin-3 on macrophage activation induced by interleukin-2,' Cancer, 71(6), 2076-2081(1993)
  8. M.C. Caroleo, D. Frasca, G. Nistico and G. Doria, 'Melatonin as immunomodulator in immunodeficient mice,' Immunopharmacology, 23(2), 81-89(1992)
  9. J. Pepping, 'Melatonin,' Am J Health Syst Pharm, 56(24), 2520-2527(1999)
  10. H. Aso, F. Suzuki, T. Yamaguchi, Y. Hayashi, T. Ebina and N. Ishida, 'Induction of interferon and activation of NK cells and macrophages in mice by oral administration of Ge-132, an organic germanium compound,' Microbiol Immunol, 29(1), 65-74(1985)
  11. A.K. Abbas and A.H. Lichtman, Cellular and Molecular Immunology, 4th Ed., pp. 260-261, Saunders, Philadelphia(2000)
  12. S. Goodman, 'Therapeutic effects of organic germanium,' Med Hypotheses, 26(3), 207-215(1998)
  13. 아사이 가즈히꼬, 게르마늄과 나, pp. 255-258, 한국관광문화연구소(1997)
  14. D.G. Jarrett, Medical Management of Radiological Casualties, 1st Ed., pp. 20-25, Armed Forces Radiobiology Research Institute, Bethesda(1999)